Novagains Biopharmaceutical

Novagains Biopharmaceutical is a clinical-stage biotechnology company specializing in the development of innovative therapies for metabolic and digestive diseases, with a primary focus on obesity, type 2 diabetes, and NASH. Based in Suzhou, China, the company leverages a proprietary peptide engineering platform to design multi-receptor agonists targeting GLP-1, GCG, and GIP pathways. Their pipeline includes long-acting peptide injectables as well as oral small molecule GLP-1 receptor agonists designed to improve patient convenience and therapeutic efficacy. Novagains aims to address the growing global burden of metabolic disorders through differentiated drug profiles and strategic clinical development.